Biosimilars, 10 Years & Counting

Since the Biologics Price Competition and Innovation Act of 2010 (BPCIA), 26 biosimilars have been approved, providing patients with lower-cost, life-changing medicines, which treat cancer, rheumatoid arthritis, Crohn’s and more, but not all of them are accessible to patients. Biosimilars are just as safe and effective as brand biologics. As Americans look for ways to lower drug costs, increasing access and use of biosimilars will provide millions of U.S. patients with the cost-saving benefits from this growing category of drugs.

Help reflect on these last ten years and discuss how to make the next ten years even better by sharing the Instagram card and including #b10similars on your social media posts to engage physicians, patients and policymakers in the journey and potential of biosimilars.

View Our Instagram Lens
With your mobile device, visit our instagram page, get our lens, & then come back here to scan the card for a surprise!

Celebrating 10 Years of Biosimilars. 10 Years and Counting.

Since the Biologics Price Competition and Innovation Act of 2010 (BPCIA), 26 biosimilars have been approved, providing patients with lower-cost, life-changing medicines, which treat cancer, rheumatoid arthritis, Crohn’s and more, but not all of them are accessible to patients. Biosimilars are just as safe and effective as brand biologics. As Americans look for ways to lower drug costs, increasing access and use of biosimilars will provide millions of U.S. patients with the cost-saving benefits from this growing category of drugs.

Help reflect on these last ten years and discuss how to make the next ten years even better by sharing the Instagram card and including #b10similars on your social media posts to engage physicians, patients and policymakers in the journey and potential of biosimilars.

View Our Insta Lens

Biosimilars Timeline

Biosimilars Timeline

Additional Resources

White Paper: Failure to Lauch.
Patent Abuse Blocks Access to Biosimilars for Patients.

Video: Learn how biosimilars are lower-cost alternatives to biologics with no clinically meaningful differences in safety or efficacy.

White Paper: Lessons from Europe’s Biosimilars Successes: Payer, Physician, and Patient Alignment Will Lower Costs, Increase Access to Biosimilars.

The Biosimilars Handbook.
The New Frontier for Improved Access to Medicines.

White Paper: Failure to Launch Part 2.
The biosimilars uptake failure.

Video: Increasing Biosimilars Access Through Stakeholder Engagement & Education.

Issue Brief: Expanding Biosimilars Use Could Save Patients, Reduce Out-of-Pocket Costs By 17 Percent.

Report. 2019 Generic Drug and Biosimilars Access and Savings in the U.S.